| Secondary |
| Depression |
54.4% |
| Product Used For Unknown Indication |
11.4% |
| Intentional Overdose |
8.8% |
| Drug Use For Unknown Indication |
7.9% |
| Hypertension |
4.4% |
| Schizophrenia, Paranoid Type |
4.4% |
| Facial Spasm |
2.6% |
| Hypothyroidism |
1.8% |
| Panic Disorder |
1.8% |
| Attention Deficit/hyperactivity Disorder |
0.9% |
| Bipolar Disorder |
0.9% |
| Irritable Bowel Syndrome |
0.9% |
|
| Suicide Attempt |
13.3% |
| Ventricular Tachycardia |
13.3% |
| Vomiting |
10.0% |
| Dyspnoea |
6.7% |
| Overdose |
6.7% |
| Panic Reaction |
6.7% |
| Paroxysmal Perceptual Alteration |
6.7% |
| Somnolence |
6.7% |
| Coma Scale Abnormal |
3.3% |
| Convulsion |
3.3% |
| Heart Rate Increased |
3.3% |
| Multiple Drug Overdose |
3.3% |
| Sensation Of Heaviness |
3.3% |
| Speech Disorder |
3.3% |
| Stevens-johnson Syndrome |
3.3% |
| Ventricular Flutter |
3.3% |
| Wrong Drug Administered |
3.3% |
|
| Concomitant |
| Drug Use For Unknown Indication |
22.7% |
| Depression |
13.5% |
| Product Used For Unknown Indication |
11.8% |
| Anxiety |
5.9% |
| Hypertension |
5.9% |
| Sleep Disorder |
5.1% |
| Insomnia |
4.4% |
| Crohn's Disease |
4.0% |
| Schizophrenia |
3.8% |
| Rheumatoid Arthritis |
3.6% |
| Diabetes Mellitus |
3.4% |
| Blood Pressure Increased |
2.1% |
| Constipation |
2.1% |
| Osteoporosis |
2.1% |
| Colitis Ulcerative |
1.7% |
| Mental Disorder |
1.7% |
| Muscle Tightness |
1.7% |
| Myocardial Ischaemia |
1.7% |
| Sedative Therapy |
1.5% |
| Urinary Incontinence |
1.5% |
|
| Vomiting |
20.3% |
| Pancytopenia |
6.8% |
| Injection Site Pain |
5.4% |
| Pyrexia |
5.4% |
| Tremor |
5.4% |
| Visual Impairment |
5.4% |
| Weight Decreased |
5.4% |
| Weight Increased |
5.4% |
| Completed Suicide |
4.1% |
| Headache |
4.1% |
| Mitral Valve Incompetence |
4.1% |
| Syncope |
4.1% |
| Transient Ischaemic Attack |
4.1% |
| Water Intoxication |
4.1% |
| Bladder Transitional Cell Carcinoma |
2.7% |
| Drug Ineffective For Unapproved Indication |
2.7% |
| Drug Interaction |
2.7% |
| Dry Mouth |
2.7% |
| Hypotension |
2.7% |
| Neuroleptic Malignant Syndrome |
2.7% |
|
